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Abstract
Adenocarcinoma of the pancreas is a lethal malignancy, and better models to study tumor behavior in vivo are needed
for the development ofmore effective therapeutics. Ionizing radiation is a treatmentmodality that is commonly used in
the clinical setting, in particular, for locally confined disease; however, good model systems to study the effect of
ionizing radiation in orthotopic tumors have not been established. In an attempt to create clinically relevant models
for studying treatments directed against pancreatic cancer, we have defined a methodology to measure the effect of
varying doses of radiation in established human pancreatic cancer orthotopic xenografts using two different pan-
creatic cancer cell lines (Panc-1 and BXPC3) infected with a lentiviral vector expressing CMV promoter–driven lucifer-
ase to allow bioluminescence imaging of live animals in real time. Quantifiable photon emission from luciferase
signaling in vivo correlated well with actual tumor growth. Bioluminescence imaging of the established pancreatic
xenografts was used to direct delivery of radiation to the orthotopic tumors and minimize off-target adverse effects.
Growth delay was observed with schedules in the range of 7.5 Gy in five fractions to 10 Gy in four fractions, whereas
doses 3 Gy or higher produced toxic adverse effects. In conclusion, we describe a model in which the effects of ioniz-
ing radiation, alone or in combination with other therapeutics, in orthotopic xenografts, can be studied.
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Introduction
Adenocarcinoma of the pancreas ranks fourth highest in cancer-related
mortality in the United States. In 2008, an estimated 34,000 people
were diagnosed with pancreatic cancer that has an overall 5-year sur-
vival of less than 5% [1]. Although major advancements have been
made in understanding the disease, effective therapeutic regimens
are still lacking. There is a great need for relevant preclinical models
to test potential therapeutics in the treatment of pancreatic cancer.
The use of animal models that mimic biological processes of cancer
seen in human disease is paramount in testing potential therapeutics.
Many researchers use human xenografts established in immune-
deficient animals to recapitulate the biologic behavior of tumors.
When implanted subcutaneously in an animal, tumor biometrics are
easy to monitor. The establishment of tumors in the subcutis, how-
ever, may not necessarily represent the most appropriate niche to study
cancers that arise in other sites because studies have shown the tumor
microenvironment to be an integral component that influences the
response of tumors to therapeutics [2–5]. In contrast, orthotopic trans-
plantation of primary human tumors in immune-deficient mice repro-
duces a pattern of local growth and distal dissemination seen in humans.
It has been shown that orthotopically implanted pancreatic tumors in
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immune-deficient mice closely mimic human tumors in their growth
and metastatic potential [6–8]. However, without in vivo imaging capa-
bility, orthotopic models require sacrifice of the animal to assess treat-
ment effect and thus limit the real time evaluation of treatment effects in
living animals.
In vivo imaging techniques of mouse models of human disease,
namely magnetic resonance imaging or computed tomographic scans,
can be costly and time-consuming. An alternative approach for in vivo
imaging is abdominal ultrasound [9], which may be less costly, but
high-throughput evaluation of therapeutics is limited by the require-
ment of highly skilled personnel to interpret the studies. The use of
fluorescence and bioluminescence has proven utility in in vivo studies
of the pancreas and other organ systems [10–12]. In this study, we in-
vestigate the effect of ionizing radiation on xenografts established ortho-
topically in nonobese diabetic–severe combined immunodeficient
(NOD/SCID) mice and develop a method to deliver ionizing radiation
treatment to orthotopically implanted pancreatic tumors based on bio-
metrics gathered from luciferase-based bioluminescent imaging.
Materials and Methods
Cell Lines
Panc-1 and BXPC3 human pancreatic cancer cells were obtained
from the American Type Culture Collection (Manassas, VA) and were
maintained in Roswell Park Memorial Institute medium containing
10% bovine serum in an atmosphere of 93% air and 7% carbon di-
oxide. Both cell lines were transduced with nonreplication competent
lenitvirus from the viral vector core of the University of Michigan
expressing a CMV promoter 5′ to the firefly luciferase protein followed
by green florescent protein tag. Pancreatic cancer cell lines were plated
at 2 × 105 cells/well in six-well plates. The cells were allowed to adhere
for 12 hours, after which the medium was replaced with 2 ml of either
1:500 or 1:5000 diluted viral concentrate. The number of cells per well
was counted at the time of virus addition, and the average of four wells
was used to calculate the viral titer. Viral supernatants remained on the
cells for 48 hours, after which the cells are analyzed for expression of
luciferase in vitro through FACS sorting for green florescent protein.
Transfection efficiency was measured to be higher than 99% when
transfection was performed with MOI = 5. Luciferase activity was
assessed by detection of photons using the Xenogen IVIS system
(Xenogen, Alameda, CA) after administration of 150 μg/ml D-luciferin
to cells incubated 2 minutes after administration of substrate.
Subcutaneous and Orthotopic Xenografts
Animals used in this study were maintained in facilities approved
by the American Association for Accreditation of Laboratory Animal
Care in accordance with current regulations and standards of the US
Department of Agriculture and Department of Health and Human
Services. The animal protocol used in this study was approved by the
University Committee on Use and Care of Animals at the University
of Michigan. For subcutaneous implantation of tumor, 1 × 106
BXPC3 or Panc-1 cells were injected subcutaneously into the flanks
of mice using a 26.5-gauge needle after deep anesthesia was induced.
To establish orthotopic xenografts, after administration of anesthesia,
a small subcostal laparotomy was performed, and BXPC3 or Panc-1
cells infected with the lentivirus-expressing luciferase (BXPC3-Luc or
Panc-1–Luc, respectively) were then injected orthotopically in concen-
trations of 1 × 106 cells in the pancreatic tail of NOD/SCID mice.
Bioluminescent Imaging
For in vivo imaging, mice were given the substrate D-luciferin
(150 mg/kg in PBS) by intraperitoneal injection immediately after
administration of anesthesia with isoflurane (1%-3%). Two minutes
after administration of substrate, the anesthetized mice were placed
onto the warmed stage inside the light-tight camera box with contin-
uous exposure to isoflurane (1%-2%). In this study, animals were
imaged 2 minutes after luciferin injection to ensure consistent photon
flux. In our study, measuring 2 minutes after luciferin injection gave
a result within a range of 15% variability. The mice were imaged
twice weekly for 21 to 28 days depending on experimental conditions
or until tumor burden was too great, as defined by significant weight
loss, development of abdominal ascites, or respiratory failure. The
acquisition time data for photon emission measurement were normal-
ized to 120 seconds. The IVIS camera system was used to visualize the
tumors, and photon measurement was defined around the tumor area
and quantified as total photon/s using Living Image software (Xenogen,
Corp, Alameda, CA). Tumor size was determined after necropsy at
varying time points, and correlation was made with average photon
emission after live animal imaging.
Irradiation
Orthotopically implanted animals were randomized to radiation
treatment or placebo once mean tumor volume reached approximately
200 mm3. Animals were irradiated in the Radiation Core of the Uni-
versity of Michigan Comprehensive Cancer Center (Ann Arbor, MI)
using a Phillips 250 Orthovoltage unit (Philips Medical Systems,
Farmington Hills, MI) at approximately 1.4 Gy/min to the animals.
Dosimetry was carried out using an ionization chamber connected to
an electrometer system directly traceable to a National Institute of
Standards and Technology calibration. Mice were anesthetized with
a mixture of ketamine 60 mg/kg and xylazine 3 mg/kg, and position-
ing was guided by bioluminescent images of the tumor signal and was
confirmed by clinical tumor palpation such that the tumor was at the
center of a 2.4-cm aperture in the secondary collimator. Mice were
focally irradiated after being appropriately shielded from radiation
using size-appropriate lead aprons fashioned to expose only the area
of tumor (adjustable lead shielding which allows exposure of area as
small as 1.0 cm) while protecting the animals. A half-beam block tech-
nique was used to ensure a nondivergence of the radiation beam edge.
Statistical Analysis
Analysis of variance was used to determine the significance of dif-
ferences of tumor photon emissions between various radiation sched-
ules. Differences between treated and untreated groups in tumor
volume were tested for significance with two-tailed Student’s t-test.
The xenograft studies were powered at 80% to detect a 30% difference
in photon emissions.
Results
Quantifiable Photon Emission Detected by Luciferase
Signaling In Vivo Is a Function of Mean Tumor Volume
Signal intensity from orthotopic tumors was measured by quantified
photon emission of the luciferase activity of tumors at different time
points after implantation. After measurement, animals were killed,
and actual tumor volume was measured. Tumor volume measurements
correlated well with mean quantified photon emission detected for
both BXPC3 and Panc-1 orthotopic xenografts. A nonlinear regression
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analysis was performed to estimate a growth curve based on photon
emission. R2 values for curve fit approached close to 1 for both xeno-
grafts: BXPC3, R2 = 0.837, P < .05; and Panc-1, R2 = 0.905, P < .01
(Figure 1). The measured luciferase activity between the two xenografts
was different. Mean photon emission of BXPC3 tumors at 300 mm3
in size was higher than Panc-1 tumors at 300 mm3 in size (3.284 e8 ±
3.106 e8 vs 1.289 e8 ± 5.583 e7 p/sec per square centimeters per stera-
dian, n = 5, P < .05).
Comparison of Subcutaneous and Orthotopically Implanted
Pancreatic Cancer Cells
Surgical implantation of luciferase expressing BXPC3 and Panc-1
(1 × 106) cells into the subcutis or orthotopically in the pancreatic
tail was performed, and tumor biometrics were compared among the
two tumor implant sites. None of the mice died of anesthetic or surgical
complications. Tumor size and metastasis were assessed at necropsy
21 days after tumor cell implantation. There was gradual tumor en-
largement of both orthotopic and subcutaneous tumors after implan-
tation, which correlated with increased photon emission based on
bioluminescent imaging. Tumor kinetics was not significantly different
between the orthotopic and subcutaneous tumors for the first 21 days;
however, the growth of the orthotopic tumors was found to plateau
from day 21 (Figure 2A). Table 1 shows necropsy results of mice im-
planted with either orthotopic or subcutaneous tumors at 21 days.
Approximately 90% (18/20 BXPC3, 17/20 Panc-1) of the orthotopic
implantations succeeded in tumor formation, whereas all of the sub-
cutaneous implantations formed tumors (8/8). Orthotopic tumor
implants had, on average, smaller tumor volume in comparison to sub-
cutaneous implants at 21 days (Figure 2B): BXPC3 tumors, 416 mm3
orthotopic versus 1145 mm3 subcutaneous; and Panc-1 tumors,
254 mm3 orthotopic versus 756 mm3 subcutaneous. There was a sig-
nificantly higher incidence of metastasis with orthotopic implants
in comparison to subcutaneous implants (23/35 [71%] of orthotopic
implants vs 2/16 [12%] of subcutaneous implants). The predominant
area of local invasion in the orthotopically implanted tumors was inva-
sion of the stomach followed by invasion of the duodenum and spleen.
The most common site of distant metastasis was the liver, followed by
lung. Liver and lung metastasis could be detected by bioluminescence
from day 10 (10 ± 4.5) and later (data not shown). However, quanti-
fication and characterization of the metastatic implants were performed
by gross examination at necropsy, and bioluminescence was reserved for
assessment of the treatment effect on the primary tumor because this
was the focus of this study. Some tumors resulted in massive tumor
growth resulting in life-threatening bowel obstruction. BXPC3 cells
were more locally aggressive in comparison to Panc-1 cells, displaying
increased tumor size when implanted orthotopically (416 vs 254 mm3,
P < .05); however, rates of metastasis were not statistically different
(14/18 vs 11/17, P = NS).
Minimal Radiation Toxicity and Good Clinical Efficacy Is
Observed with Fractionated Dosing Regimens of 1.5 to 2 Gy
per Fraction
The effect of radiation on tumor growth was determined using a
number of fractionated regimens, with the dose per fraction varying
from 1.5 to 3 Gy. Tumor suppression was seen with all doses of frac-
tionated radiation in both cell lines (Figure 3A). The degree of tumor
suppression was proportional to the increase in radiation dose used. Sig-
nificant toxicity was seen with radiation doses of 3 Gy. Non–tumor-
bearing animals were irradiated, and weight loss was determined as a
measure of toxicity. Significant weight loss occurred at a radiation dose
of 3 Gy, with greater than 30% weight loss occurring 5 days after ra-
diation (data not shown). With 1.5 to 2 Gy doses administered for
5 days, only a 5% to 10% reduction in weight occurred at day 5, and
stable weights resumed (Figure 3B). With 2.5 Gy of radiation adminis-
tered daily for 4 days, a mean of 25% weight loss occurred during ion-
izing radiation treatment but regained weight once treatment ceased
Figure 1. Quantifiable photon emission from luciferase signaling in vivo is a function of mean tumor volume. Regression analysis of mean
photon emission as a function of tumor volume showed that R2 values approached 1. For BXPC3 tumors, the R2 curve fit was 0.837 (P <
.05); for Panc-1 tumors, this was 0.905 (P < .01).
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(Figure 3B). On the basis of these data, the range of dose of ionizing
radiation that produced tumor growth delay without undue toxicity
was between 1.5 Gy × 5 fractions (7.5Gy total) and 2.5 Gy × 4 fractions
(10 Gy total); doses beyond this level produced toxic adverse effects.
Quantifiable Photon Emission from In Vivo Luciferase
Activity Correlated with Tumor Growth Suppression from
Ionizing Radiation
The measured signal intensity of BXPC3 and Panc-1 xenografts
showed significant reduction in luciferase activity after ionizing radia-
tion treatment (Figure 4A). The mean quantified photon emission of
BXPC3 tumors at 10 days after 2.5 Gy × 4 fractions was significantly
less than control tumors: 3.781 e8 ± 3.330e8 p/sec per square centimeters
per steradian (untreated) versus 1.332 e8 ± 8.359e7 p/sec per square
centimeters per steradian (treated), n = 4, P < .05 (Figure 4B, left panel ).
A similar decrease in luciferase signal intensity was seen in Panc-1 xeno-
grafts at 10 days after radiation treatment of 2.5 Gy × 4; 2.429 e8 ±
2.12 e8 p/sec per square centimeters per steradian (untreated) versus
1.304 e8 ± 5.917 e7 p/sec per square centimeters per steradian (treated),
n = 4, P < .05 (Figure 4B, right panel ). A significant reduction in tumor
Figure 2. Comparison of subcutaneous and orthotopically implanted cancer cells. Comparison of tumor kinetics and growth between
subcutaneous and orthotopic xenografts of BXPC3 (right) and Panc-1 (left) after implantation of 1 × 106 cells. (A) Each data point consists
of tumor analysis from four animals. (B) Mean tumor volume of subcutaneous and orthotopic tumors at 7 and 21 days.
Table 1. Primary and Metastatic Growth of BXPC3 and Panc-1 Orthotopic and Subcutaneous Xenografts in NOD/SCID Mice.
No. Implanted Graft Take Stomach Invasion Duodenal Invasion Spleen Invasion Liver Met Lung Met Bowel Met Peritoneum No. Animals
with Distant Met
Orthotopic implants
BXPC3 20 18 18 15 8 8 7 6 11 14
Panc-1 20 17 16 15 5 6 4 3 9 11
Subcutaneous implants
BXPC3 8 8 0 0 0 1 1 0 2 2
Panc-1 8 8 0 0 0 0 0 0 1 1
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volume was seen at the 10-day period of BXPC3 tumors: 441 ±
105.1 mm3 (untreated) versus 163 ± 90.73 mm3 (treated), n = 4, P <
.05 (Figure 4C , left panel ). The effect of radiation on Panc-1 xenografts
was also significant, where mean tumor volume was greater in the un-
treated group (286.7 ± 105.9 mm3) compared with the treated group
(111.0 ± 40.9 mm3; n = 4, P < .05; Figure 4C , right panel ). After the
cessation of treatment, tumor suppression abated, and tumor recovery
and growth were observed in BXPC3 xenografts 21 days after radiation
treatments were stopped. In the Panc-1 xenografts, tumor volume at
28 days after radiation treatment showed continued tumor suppression.
In contrast, in the BXPC3 tumors, there was a small tumor mass reduc-
tion that did not reach statistical significance (Figure 4C , left panel ). The
mean tumor volume of BXPC3 xenografts at 28 days after radiation
treatment was 667.7 ± 120.6 versus 768.4 ± 133.3mm3 in nonirradiated
controls, n = 4,P =NS.Mean tumor volume of Panc-1 tumors at 28 days
after randomization was measured to be 574.0 ± 79.5 mm3 in the un-
treated arm of the experiment versus 253 ± 77.1 mm3 in the treated
animals (n = 4, P < .05).
Discussion
In this report, we demonstrate the successful use of bioluminescence im-
aging to direct radiation delivery to orthotopic pancreatic cancer xeno-
grafts, an animal model of pancreatic cancer that faithfully recapitulates
some of the most important features of the human malignancy, such
as local invasion and metastasis. We also show that bioluminescence
allows monitoring of tumor biometrics by both visualization of spread
and quantification of tumor size in real time in the same animal as they
undergo treatment.
The use of luciferase activity to measure tumor biometrics after anti-
tumor therapy has been described previously [13]. However, there are
only few reports on the use of radiation to treat orthotopic xenografts,
and they are mostly found in prostate and brain tumor research
Figure 3. Minimal radiation toxicity is observed with fractionated dosing regiments of 2 to 2.5 Gy. Orthotopic xenograft response to irradia-
tion. Animals were randomized to irradiation versus placebo once they reached a tumor volume of approximately 200 mm3. (A) All tested
radiation schedules reduced orthotopic tumor volume. Each data point is the analysis of data from four animals. (B) Animal weight changes
were minimal (<10% decline) with 1.5- to 2.5-Gy fraction doses of radiation. Each data point consists of tumor analysis of eight animals.
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Figure 4. Quantifiable photon emission from in vivo luciferase signaling correlated with tumor suppression from ionizing radiation. Mice
implanted orthotopically with BXPC3-Luc or Panc-1–Luc were treated with placebo or four fractions of 2.5 Gy. Same four mice from each
treatment group are shown in consistent pairings throughout the experiment. (A) Some figures may illustrate means of data acquisition
(red ovals) used to quantify photon emission. (B) Both tumor lines experienced growth delay after irradiation, as measured by photon emis-
sion. (C) Collectionof the tumors at day10after radiation therapy revealeddetectabledifferences in tumor size inboth xenografts.However, at
day 28 after cessation of radiation, only Panc-1 tumors continued to show tumor suppression.
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[14–16]. Previous work in brain tumors has entailed the use of one [14]
or two [15] fractions in nude mice and has focused on the study of
short-term effects, without attempting to maintain the animals alive
for prolonged periods. Freytag et al. [16] did use SCID mice, but they,
too, delivered only two fractions. Our work is unique in the application
of in vivo bioluminescence image guidance to direct radiation focally
at a target surrounded by sensitive abdominal organs in an extra-
ordinarily radiosensitive animal. Using this method, we described a
range of multifraction dose schedules (that better approximate clinical
radiotherapy regimens), which allow a quantitative assessment of the
antitumor effect of radiation, during a protracted period.
In our study, we did find differential luciferase activity between the
two tumor cell lines BXPC3 and Panc-1. As both tumor lines were ana-
lyzed to have equivalent transfection efficiencies, differential expression of
luciferase does not explain the findings we see in this study. To put it
simply, it is possible that there are less tumor cells in Panc-1 tumors; this
may result in less emission.When tumors were further analyzed histologi-
cally, a more potent peritumoral desmoplasia was seen in Panc-1 tumors.
We believe that enhanced stromal proliferationmay contribute to the dis-
crepancy seen in luciferase activity between Panc-1 and BXPC3 tumors.
Stromal proliferation leading to desmoplasia may play a significant role in
inhibition of the luciferin penetrance and delivery to tumor cells or result
in a relative inhibition of photon emission within these tumors. Alter-
natively, the density of cancer cells within the more desmoplastic tumor
microenvironment may be less, resulting in a weaker luciferase signal.
In summary, the data we present demonstrate that luciferase imaging
of orthotopically established pancreatic xenografts accurately assesses
tumor growth in vivo. Importantly, orthotopic radiation ofNOD/SCID
mice is feasible without compromising overall mouse survival allowing
for longitudinal studies of tumor treatment effect and outcome. This
novel system for studying in vivo tumor growth and suppression
provides a clinically relevant model for assessing the efficacy of various
therapeutics used in combination with radiation. As such, it represents
an important tool in the development of new, more effective, regimens
to be used in unresectable tumors as well as in the adjuvant or neo-
adjuvant setting. In addition, this system may also be a useful inves-
tigative model to locate and harvest residual tumors in treated animals
to study mechanisms underlying resistance to therapy.
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